Mark Pegram

15PUBLICATIONS
68CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Economic models and forecastingPredictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 09, 2026
Beyond Amplification: Precision Approaches to Targeting HER2.

|Dec 09, 2025
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

Xiaosong Chen, Jiahui Huang, Haoting Shi

|Nov 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Hope S Rugo, Virginia Kaklamani, Heather McArthur

|Nov 18, 2023
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data.

Nancy U Lin, Priya Kumthekar, Solmaz Sahebjam

|Jun 28, 2023
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.

Giuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac

|May 31, 2023
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.

Mark Pegram, Christian Jackisch, Stephen R D Johnston

Pageof 3

Frequent Collaborators

4 joint publications

Nancy U Lin

3 joint publications

Nuhad Ibrahim

2 joint publications

William J Gradishar

2 joint publications

Whitney Kirschbrown